tbuckley/cabot-search huggingface dataset:
Abstract 15074: Safety and Efficacy of Peri-Procedural Heparin Plus Short Term Infusion of Tirofiban Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From The Intermountain Heart Collaborative Study
Authors: Joseph B Muhlestein, Heidi T May, Tami L Bair, Viet T Le, Jeffrey L Anderson, Brian K Whisenant, Kirk U Knowlton, Donald L Lappe
Journal: Circulation (2016)

Introduction: A primary conflict in anticoagulation during percutaneous coronary intervention (PCI) is the simultaneous desire to prevent both thrombosis and bleeding. In modern PCI with standard dual oral antiplatelet therapy, the use of heparin + short (<6 hrs) infusions of glycoprotein IIb/IIIa inhibitors, or short infusions of bivalirudin alone, have been proposed as potentially superior alternatives to heparin plus more prolonged infusions. However, which strategy of short term anticoagulation during PCI is best is unknown. Therefore, we compared the safety and efficacy of heparin plus short term infusions of tirofiban (S-tirofiban) versus bivalirudin during elective or urgent PCI.

Methods: From January 2013 to December 2015, patients who underwent successful PCI without cardiogenic shock and were anticoagulated using S-tirofiban or bivalirudin were studied. TIMI major bleed (including any transfusion) at 30 days and death, nonfatal MI and urgent target vessel revascularization (UTVR) at 1 year were ascertained.

Results: A total of 402 PCI patients receiving S-tirofiban (age=64±13 yrs, males=75%, diabetes = 39%, smokers=26%, acute coronary syndrome presentation (ACS) = 77%) and 455 patients receiving bivalirudin, (age=65±13 yrs, males=71%, diabetes = 42%, smokers=26%, ACS=79%) were included. TIMI major bleed was 1.2% and 3.1% for S-tirofiban and bivalirudin respectively. Adverse events at 1 year were death (3.4% and 5.5%), MI (2.9% and 3.0%), UTVR (2.0% and 1.5%) for S-tirofiban and bivalirudin respectively. See table for multivariable results.

Conclusion: During PCI, when comparing the efficacy of S- tirofiban versus bivalirudin, no significant differences for 30 day TIMI major bleeding or 1 year death, MI or UTVR were identified. Although trends towards reductions in both TIMI major bleeding and death were observed with the use of S-tirofiban, due to the generally low incidence of any adverse events, no statistical significance was reached.

   ![][1]  [1]: /embed/graphic-1.gif
Hematologic and Hospitalization Outcomes in Patients with Chemotherapy-Induced Anemia (CIA) Treated with Erythropoiesis-Stimulating Agents (ESAs) in the Pre- Vs Post-National Coverage Determination (NCD) Time Periods.
Authors: Elizabeth Apgar, Tanya M. Burton, Kay Larholt, Chris L. Pashos, Lorie Ellis, Mekré Senbetta, R. Scott McKenzie
Journal: Blood (2009)
The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.
Authors: Wenjing Tao, Tong Sun, Adam R. Craig, Jorge E. Cortes, Oliver G. Ottmann, Andreas Hochhaus, Premkumar E. Reddy, Hagop M. Kantarjian, Ralph B. Arlinghaus
Journal: Blood (2006)
Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”.
Authors: Nitin Jain, Gloria N. Mattiuzzi, Jorge Cortes, Jennifer Cassat, Guillermo Garcia-Manero, Farhad Ravandi-Kashani, Sherry Pierce, Gautam Borthakur, Susan O’Brien, Hagop M. Kantarjian
Journal: Blood (2007)
Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.
Authors: Youn H Kim, Marie-France Demierre, Ellen J Kim, Alain H Rook, Adam Lerner, Madeleine Duvic, Sunil Reddy, Tadeusz Robak, Jürgen C Becker, Alexey Samtsov, William McCulloch, Sean Whittaker
Journal: Blood (2009)
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes
Authors: Federica Loscocco, Giuseppe Visani, Elisa Giacomini, Annamaria Ruzzo, Sara Galimberti, Maria Teresa Voso, Carlo Finelli, Elena Ciabatti, Emiliano Fabiani, Francesco Graziano, Sara Barulli, Antonio Volpe, Domenico Magro, Pier Paolo Piccaluga, Fabio Fuligni, Marco Vignetti, Paola Fazi, Alfonso Piciocchi, Cristina Clissa, Elisa Gabucci, Marco Rocchi, Mauro Magnani, Alessandro Isidori
Journal: Blood (2015)
TMIC-15MYELOID DERIVED SUPPRESSOR CELLS' TRAFFICKING INTO GBM IS REGULATED BY CXCR2 SIGNALING
Authors: Neha Kamran, Stefanie Stallard, Nicholas Raja, Mariela-Moreno Ayala, Alexandra Calinescue, Felipe Nunez, Anuska Andjelkovic, Pedro Lowenstein, Maria Castro
Journal: Neuro-Oncology (2015)
Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group.
Authors: Martin Stanulla, Elke Schäffeler, Silke Pohlschmidt, Martin Zimmermann, Anja Möricke, Gunnar Cario, Andre Schrauder, Karl Welte, Jochen Harbott, Wolf-Dieter Ludwig, Alfred Reiter, Michel Eichelbaum, Martin Schrappe, Matthias Schwab
Journal: Blood (2009)
Treosulfan-Based Myeloablative Conditioning for Autologous Stem Cell Transplantation In Elderly Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: Data of Feasibility and Efficacy In 10 Patients.
Authors: Massimo Bernardi, Carlo Messina, Michela Tassara, Alessandro Crotta, Fabio Giglio, Andrea Assanelli, Daniela Clerici, Consuelo Corti, Magda Marcatti, Simona Malato, Barbara Forno, Jacopo Peccatori, Fabio Ciceri
Journal: Blood (2010)
Ancestim (r-metHuSCF) in Combination with Filgrastim To Rescue Mobilization and Collection of Peripheral Blood Progenitor Cells for Autologous Transplantation. Compassionate Use in 372 Patients at 68 Sites in France (1998–2004).
Authors: Jean-Francois Rossi, Karima Safsafi, Peter Royce, Jean Caraux
Journal: Blood (2004)
THU0476 Efficacy of Denosumab for The Treatment of Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Authors: K. Oh, O. Namiki, Y. Toyoshima, K. Inagaki, K. Kanbe, J. Chiba
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Recent studies have reported that RA patient with osteoporosis administered Denosumab (DMAB) was associated with significant increases of low bone mineral density (BMD) at lumbar spine and femoral neck. DMAB increases cortical bone more effective than any other drug for treatment of osteoporosis. <h3>Objectives</h3> Therefore, we investigated efficacy of DMAB in the patient with RA for 12 months at lumbar spine, femoral neck, and radius. <h3>Methods</h3> Sixty RA patients with osteoporosis were administered DMAB between April 2014 and October 2015, 45 patients were evaluated for 12 months in our institute. The following items were examined just before administered and at the time of 6 months and 12 months after administration: BMD of lumbar/femur/radius, Biomarker (total P1NP, TRACP-5b), radiograph of the hand. Also, comparisons were performed on the basis of efficacy of DMAB at the time of 12 months in radius between the patients with the poorly effected group (NR group), and the patients with the well-effected group (R group). <h3>Results</h3> After treatment of DMAB at 12 months, 5.2 percent increase of BMD at the lumbar spine was obtained, 4.2 percent increase at the femoral neck. However, there was not significant change at the distal third of the radius. Comparing the NR group to the R group, there was statistically significant difference in Larsen grade at the wrist. <h3>Conclusions</h3> DMAB significantly increases bone mineral density in the patient with RA. However, in the patient with severe joint destruction, DMAB could not increase BMD at the radius. <h3>Disclosure of Interest</h3> None declared
PTU-006 The Value of EUS in Diagnosing Liver Hilar Lesions
Authors: B Maher, C Forde, A Pallan, R Boulton, C Shekhar, BS Mahon
Journal: Gut (2016)

<h3>Introduction</h3> The aetiology of liver hilar strictures remains a challenging area to diagnose. Advances in cross sectional imaging have improved our ability to better delineate these lesions. However, in the absence of a significant mass, benign and malignant disease may demonstrate similar imaging features, underlining the importance of obtaining a definitive tissue diagnosis prior to potential surgery or chemotherapy. As both treatments carry significant morbidity, and mortality in the case of surgery, obtaining an accurate diagnosis remains imperative. Obtaining a pathological diagnosis remains challenging in particular as the liver hilum is not easily amenable to percutaneous tissue sampling. The yield of endobiliary techniques, principally ERCP guided brushings and endobiliary biopsy is reported to range widely between 33% and 80%, and in practice remains low. Although these methods are highly specific for diagnosis of malignancy, they have a low sensitivity, ranging between 46% and 73%. EUS is a powerful tool in the assessment of hilar lesions with an ability to perform FNA and obtain tissue. We sought to assess the ability of EUS to make a positive diagnosis in these lesions. <h3>Methods</h3> A retrospective review was performed on all patients who were referred with a hilar mass or stricture that proceeded to EUS assessment between 2009 and April 2015. Hilar lesions were defined as those involving the common hepatic duct (i.e. proximal to the cystic duct insertion) and/or confluence of the right and left intrahepatic ducts. Assessment involved review of patient medical records, EUS findings, cytological results, pre and post procedure imaging up to 12 months post EUS FNA and clinical outcomes. <h3>Results</h3> 129 patients underwent EUS FNA, of which 76 were male, 53 were female and the mean age was 61 years old. 3 patients were excluded due to lack of follow up data. 87 (67.4%) patients were diagnosed with malignant disease, of which 93% had cholangiocarcinoma. 83% of those with a positive diagnosis were acquired in the first biopsy. EUS FNA had a sensitivity of 83%, specificity of 100%, positive predictive value of 100% and a negative predictive value of 66%. <h3>Conclusion</h3> This is the largest such series to date in the published literature. In obtaining a diagnosis from a hilar lesion, EUS proves superior to other techniques such as endobiliary biopsy. It is a highly sensitive and specific technique and should be considered as a first line in assessment of lesions in this challenging area. <h3>Disclosure of Interest</h3> None Declared
A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma: Association Between Advanced Age and Mutations in TET2 and DNMT3A
Authors: Oliver Weigert, Nadja Kopp, Sudha Bolla, Oreofe Odejide, Dan Toscano, Matthew A Lunning, Julie Teruya-Feldstein, Abner Louissaint, Scott J. Rodig, Steven M. Horwitz, David Weinstock
Journal: Blood (2012)
SP0136 User Involvement in The Development of Ehealth Products
Authors: S. Van Der Weegen
Journal: Annals of the Rheumatic Diseases (2016)

Technology has the potential to improve quality and efficiency of healthcare. It is important to involve end users in the design process of new technologies and interventions at an early stage to enhance the fit between the user, technology, and the organization of care. It improves usability, prevents the inclusion of unnecessary features and maximizes the likelihood of a successful adoption. This presentation gives an example of user involvement during the development of an eHealth intervention to stimulate physical activity in people with type 2 diabetes or COPD and will try to inspire you to co-create with end users by providing different methods for user involvement. <h3>Disclosure of Interest</h3> None declared
AB0567 Aortic Involvement in A Retrospective Cohort of Large Vessel Vasculitis Patients
Authors: M. Bellan, R. Bonometti, A. Rossini, A. Gibbin, D. Sola, R. Pedrazzoli, M. Tran Minh, M. Pirisi, P.P. Sainaghi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Large vessel vasculitis include Giant cell arteritis (GCA) and Takayasu9s disease. Both these conditions can be associated with aortic inflammatory involvement, detectable by FDG-PET. Aortitis is an indicator of a more severe clinical course of disease. <h3>Objectives</h3> We aimed to evaluate the different clinical phenotypes of large vessel vasculitis in a retrospective cohort of patients followed-up at our immunorheumatology outpatient clinic. We further aimed to identify predictors of aortic disease. <h3>Methods</h3> We retrospectively reviewed all the clinical records of patients receiving a diagnosis of large vessel vasculitis from 1st January 2010 to 1st January 2016. Clinical, laboratory, hystopathological and imaging data were collected. Non-parametric statistical analysis was performed. <h3>Results</h3> We recorded 42 diagnosis of large vessel vasculitis along a 5-year follow-up. Out of them 6 patients were not included in the analysis because of the lack of clinical informations. Median age of general population was 72.5 [64.0–76.0]; at onset, median ESR was 56 mm/h [44–75], while CRP was 6.9 mg/dl [3.4–12.1]. Median follow-up was 12 months [6–28]. 25/36 patients were female (69.4%); headache was the commonest onset symptom (28 cases, 77.8%), while polymyalgia rheumatic was diagnosed in 10 patients (27.8%). Half of the patients underwent a PET to rule out aortitic involvement, which was detected in 14/18 patients. The prevalence of aortic involvement was higher in male (7/11, 63.6%) than in female (7/25, 28%; p=0.04). Headache was always reported in uncomplicated GCA, while it was less frequent in aortitic patients (6/14 patients, 42.8%; p=0.0007). No differences were found with respect to age and laboratory data between patients with and without aortic involvement. <h3>Conclusions</h3> Large vessel vasculitis are quite common diseases in elderly people. A subset of patients, characterized by aortic involvement and a more severe prognosis can be detected. The absence of headache and male sex are risk factors for aortitis. <h3>Disclosure of Interest</h3> None declared
AB0831 Low Education Level as A Predictor of Gout in Western Sweden: Table 1.
Authors: V. Sigurdardottir, L.T. Jacobsson, A. Svärd, P. Drivelegka, M. Dehlin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout was previously regarded a disease of the affluent. Knowledge about the association between gout and socioeconomic status in modern times is limited. <h3>Objectives</h3> To investigate the association between gout and socioeconomic factors in a population based register study in a large region in Sweden. <h3>Methods</h3> All patients receiving ≥2 diagnoses of gout on at least two separate occasions in primary or secondary care or 1 diagnosis by a specialist in Rheumatology in Västra Götaland in the years 2007–2012 were identified by ICD10 codes in a regional database of health-care utilization. 3189 such patients were identified. The date of the first diagnosis was defined as the index date. A previous validation study of cases identified in this manner confirmed that this case definition is highly consistent with a diagnosis of gout as defined by established criteria (PPV &gt;80%)(1). For each case, up to 5 controls matched for age, gender and place of residence at the time of the first gout diagnosis were chosen by the Statistics Sweden agency (SCB) (N=14946). Common comorbidities known to be associated with gout (ischemic heart disease, heart failure, atrial fibrillation, hypertension, hyperlipidemia, diabetes and renal failure) prior to the index date were retrieved from the regional database of health-care utilization based on ICD10-codes. Data on education level and income at the index year was collected from the Longitudinal Integration Database for health Insurance and Labor market studies (LISA). The database holds annual registers since 1990 on all individuals above 16 years of age registered in Sweden. <h3>Results</h3> Data on education level and income was analyzed for cases and controls belonging to the working-age population as defined in Sweden (aged 15–74 years). Shorter education, &lt;12 years, was significantly more common among cases. Yearly income was lower among cases irrespective of educational length (Table 1). Cases had significantly more pre-index comorbidities compared to the controls. In a subgroup analysis of 1084 cases and 6117 controls of working age without any cardiovascular- or renal comorbidity, educational level and income was still significantly lower among cases (data not shown). <h3>Conclusions</h3> Low education level and income are predictors for gout in the working age population. The effects of education do not seem to be largely/only mediated via cardiovascular- or renal comorbidity, supporting that other factors possibly related to lifestyle or occupational exposures are of importance for gout development. <h3>References</h3> Dehlin M, Stasinopoulou K, Jacobsson L. Validity of gout diagnosis in Swedish primary and secondary care – a validation study. BMC Musculoskelet Disord. 2015;16:149. <h3>Disclosure of Interest</h3> None declared
Seasonal Influence on Growth, Function and Inheritance
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0285 Effect of Anti-Rheumatic Treatment on Periodontal Status in Rheumatoid Arthritis Patients: A Pilot Study
Authors: M.J. de Smit, M.D. Posthumus, A.-M. van Brenk, L. Oosting, G. Springer, E. Brouwer, M. Bijl, J. Westra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Overlapping molecular pathways of inflammation have been implicated in periodontitis and rheumatoid arthritis (RA). The presence of shared underlying inflammatory pathogenesis mediating the progression of periodontitis and RA could provide potentially important common therapeutic targets. <h3>Objectives</h3> The primary purpose of this observational study was to determine the effect of methotrexate (MTX) and anti-TNFα (etanercept) on clinical parameters of periodontitis. Influence of periodontitis on efficacy of medical treatment of RA was a secondary endpoint. <h3>Methods</h3> Fourteen treatment-naïve patients starting with MTX and 12 patients starting with anti-TNFα therapy, fulfilling the ACR/EULAR classification criteria for RA (2010), older than 18 years, and with natural dentition were included. One patient was excluded because of antibiotic use for oral infection &lt;3 months prior to the study. Four patients stopped treatment with etanercept after the first follow up visit because of patient related factors. Before starting medical treatment for RA and after 2 months (MTX) or 3 months (anti-TNFα), periodontal inflammatory burden was quantified with the periodontal inflamed surface area (PISA) (Nesse et al. 2008). Subgingival presence of <i>P. gingivalis</i> was determined by anaerobic culture. In addition, radiographic intra-oral pathologies (furcation involvement, peri-apical pathology and cariës) were assessed on panoramic radiographs. Oral hygiene was measured using full mouth plaque scores. Efficacy of anti-rheumatic treatment was measured by change in RA disease activity (DAS28-ESR). <h3>Results</h3> Treatment with MTX of anti-TNFα significantly improved DAS scores (both p&lt;0.001) and erythrocyte sedimentation rates (ESR) (both p&lt;0.05). PISA did not change significantly after starting with treatment with MTX or anti-TNFα. Also, PISA or presence of other intra-oral pathologies were not associated with changes in DAS scores and ESR <h3>Conclusions</h3> Anti-rheumatic treatment did not have significant impact on clinical periodontal parameters. Within the limitations of this study (PISA scores were rather low) PISA and presence of other intra-oral pathologies were not of associated with efficacy of anti-rheumatic treatment. <h3>References</h3> Nesse, W., Abbas, F., van der Ploeg, I., Spijkervet, F.K., Dijkstra, P.U. &amp; Vissink, A. (2008) Periodontal inflamed surface area: quantifying inflammatory burden. J.Clin.Periodontol. 35, 668–673. <h3>Disclosure of Interest</h3> M. de Smit: None declared, M. Posthumus: None declared, A.-M. van Brenk: None declared, L. Oosting: None declared, G. Springer: None declared, E. Brouwer: None declared, M. Bijl Grant/research support from: Pfizer, J. Westra: None declared
Outcome of Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: Comparison of Matched Related Donor Verses Matched Unrelated Donor. Important Role of Graft Versus Host Disease in Preventing Relapse.
Authors: Adam Gassas, Lillian Sung, Prabodh Das, Jonanne K. Hitzler, Ronald Grant, Sheila Weitzman, John J. Doyle
Journal: Blood (2004)
Comparing the Efficacy of Aspirin or Low Molecular Weight Heparin or Vitamin K Antagonists in the Risk of Thromboembolic Events in Patients with Multiple Myeloma Treated with Lenalidomide-Based Therapy
Authors: Martha L Louzada, Maria-Victoria Mateos, Lenicio Siqueira, Jose-Maria B Bermejo, Enrique M Ocio, Jose-Ramon Porras
Journal: Blood (2015)
Exaggerated Response To Toll-Like Receptor Agonist Contributes To Excessive TNF Production In Myeloproliferative Neoplasm
Authors: Angela G. Fleischman, Samuel B Luty, Michael R Garbati, J Blair Edmiston, Lacey R Royer, Dorian H LaTocha, Grover C. Bagby, Brian J. Druker
Journal: Blood (2013)